 |
Rockville, Maryland, USA and Suzhou, ChinaApril 22, 2026 /PRNewswire/ — Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855), a leading biopharmaceutical company dedicated to developing innovative drugs in oncology and other areas, announced that six clinical studies on three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, with three receiving rapid oral presentations. The three key candidates are Olverembatinib (brand name: Nailike®), China’s first approved third-generation BCR-ABL inhibitor; Lisaftoclax (brand name: Lishengtuo®), China’s first approved domestically developed selective Bcl-2 inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor.
The annual ASCO meeting is one of the most important and authoritative academic exchange events in the global oncology field, showcasing the latest cutting-edge clinical oncology research achievements and cancer treatment technologies. This year’s ASCO Annual Meeting will be held from May 29 to June 2 (local US time) at the McCormick Convention Center in Chicago, in a hybrid format combining online and in-person participation.
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, stated: “This marks the ninth consecutive year that Ascentage Pharma has presented at the ASCO Annual Meeting. We are delighted to once again showcase our global innovation and R&D capabilities on this premier international academic stage. This year, multiple studies on our pipeline candidates have been selected, including three for rapid oral presentations, further validating the high recognition of the clinical value of our proprietary drugs by the international academic community. We look forward to sharing more detailed data during the meeting and continuing to accelerate our global clinical development to bring more treatment options to patients as soon as possible.”
The clinical research progress that Ascentage Pharma will present at this year’s ASCO Annual Meeting includes:
Rapid Oral Presentations
Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
Abstract Number: 6513
Presentation Format: Rapid Oral Presentation
Session Title: Hematologic Malignancies—Leukemia, MDS, and Allotransplant
Presentation Time:
May 30, 2026, 1:15 PM – 2:45 PM (Central Daylight Time)
May 31, 2026, 2:15 AM – 3:45 AM (Beijing Time)
First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA
Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
Abstract Number: 6510
Presentation Format: Rapid Oral Presentation
Session Title: Hematologic Malignancies—Leukemia, MDS, and Allotransplant
Presentation Time:
May 30, 2026, 1:15 PM – 2:45 PM (Central Daylight Time)
May 31, 2026, 2:15 AM – 3:45 AM (Beijing Time)
First Author: Professor Weiming Li, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Abstract Number: 10012
Presentation Format: Rapid Oral Presentation
Session Title: Pediatric Oncology II
Presentation Time:
May 30, 2026, 8:00 AM – 9:30 AM (Central Daylight Time)
May 30, 2026, 9:00 PM – 10:30 PM (Beijing Time)
First Author: Professor Yizhuo Zhang, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Poster Presentations
Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
Abstract Number: 11539
Presentation Format: Poster Presentation
Session Title: Sarcoma
Presentation Time:
June 1, 2026, 1:30 PM – 4:30 PM (Central Daylight Time)
June 2, 2026, 2:30 AM – 5:30 AM (Beijing Time)
First Author: Professor Haibo Qiu, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
Abstract Number: TPS6608
Presentation Format: Poster Presentation
Session Title: Hematologic Malignancies—Leukemia, MDS, and Allotransplant
Presentation Time:
June 1, 2026, 9:00 AM – 12:00 PM (Central Daylight Time)
June 1, 2026, 10:00 PM – June 2, 2026, 1:00 AM (Beijing Time)
First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA
A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
Abstract Number: TPS7101
Presentation Format: Poster Presentation
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presentation Time:
June 1, 2026, 9:00 AM – 12:00 PM (Central Daylight Time)
June 1, 2026, 10:00 PM – June 2, 2026, 1:00 AM (Beijing Time)
First Author: Matthew Steven Davids, MD, Dana-Farber Cancer Institute, USA
About Ascentage Pharma
Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855) is a comprehensive global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs to address unmet clinical needs in oncology for patients worldwide. The company has established a rich pipeline of innovative drug candidates, including inhibitors targeting key proteins in apoptosis pathways such as Bcl-2 and MDM2-p53, next-generation inhibitors targeting kinase mutations arising in cancer treatment, and protein degraders.
The company’s core drug, Nailike®, is China’s first approved third-generation BCR-ABL inhibitor, approved for the treatment of patients with chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP) harboring the T315I mutation, as well as adult patients with CML-CP who are resistant and/or intolerant to first- and second-generation TKIs. All approved indications for this drug have been included in China’s National Reimbursement Drug List (NRDL). Currently, Ascentage Pharma is conducting three global registrational Phase III clinical studies for Nailike®: the POLARIS-1 study, authorized by the US FDA and European EMA, evaluating Nailike® in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients; the POLARIS-2 study, authorized by the US FDA and European EMA, evaluating Nailike® in previously treated adult CML-CP patients; and the POLARIS-3 study, evaluating Nailike® in patients with SDH-deficient GIST.
Another key drug from the company, Lishengtuo®, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lishengtuo® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Currently, Ascentage Pharma is conducting four global registrational Phase III clinical studies for Lishengtuo®: the GLORA study, authorized by the US FDA and European EMA, evaluating Lishengtuo® in combination with a BTK inhibitor in CLL/SLL patients who have received BTK inhibitor therapy for more than 12 months with suboptimal response; the GLORA-2 study, evaluating Lishengtuo® as first-line treatment in treatment-naïve CLL/SLL patients; the GLORA-3 study, evaluating Lishengtuo® as first-line treatment in newly diagnosed elderly or unfit AML patients; and the GLORA-4 study, authorized by the US FDA and European EMA, evaluating Lishengtuo® as first-line treatment in newly diagnosed intermediate- to high-risk MDS patients.
Leveraging its strong R&D capabilities, Ascentage Pharma has established a global intellectual property portfolio and entered into global collaborations with numerous leading biopharmaceutical companies, including Takeda, AstraZeneca, Merck, Pfizer, and Innovent, as well as academic research partnerships with institutions such as Dana-Farber Cancer Institute, Mayo Clinic, the National Cancer Institute, and the University of Michigan. For more information, please visit https://ascentage.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact in this press release may constitute forward-looking statements, including opinions, expectations, beliefs, plans, objectives, assumptions, or projections of Ascentage Pharma regarding future events, operating results, or financial condition.
These forward-looking statements are subject to numerous risks and uncertainties, as detailed in documents filed by Ascentage Pharma with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” sections in the registration statement on Form F-1 (as amended) filed on January 21, 2025, and the Form 20-F filed on April 16, 2025, as well as the “Forward-Looking Statements” and “Risk Factors” sections in the initial public offering prospectus filed on October 16, 2019, and other documents we file from time to time with the SEC or HKEX. These factors could cause actual results, performance levels, operating results, or achievements to differ materially from those expressed or implied in the forward-looking statements. The statements in this forward-looking statement do not constitute a profit forecast by the company’s management.
Accordingly, such forward-looking statements should not be regarded as predictions of future events. The forward-looking statements in this press release are based solely on Ascentage Pharma’s current expectations and judgments regarding future developments and their potential impact and speak only as of the date of such statements. Ascentage Pharma undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.